rs4987188 — MSH2 Gly322Asp

Missense variant in the MSH2 connector domain (c.965G>A, p.Gly322Asp) that substitutes glycine for aspartate at a conserved structural position; classified benign for Lynch syndrome, but carriers transmit significantly more germline microsatellite de novo mutations to offspring, reflecting subtly reduced mismatch repair fidelity in germ cells

See your personal result for MSH2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MSH2 Gly322Asp — A Germline Fidelity Modifier in the Mismatch Repair Gate

Your genome is copied and transmitted to the next generation in sperm and eggs. Every round of cell division during gametogenesis introduces errors — and the mismatch repair (MMR) system11 mismatch repair (MMR) system
the cellular machinery that corrects base mismatches and insertion/deletion errors after DNA replication catches most of them before they become permanent. MSH2 is the central scaffold of this system: it forms the MutSα heterodimer with MSH6 to detect mismatches, and the MutSβ heterodimer with MSH3 to handle larger insertion/deletion loops. The Gly322Asp variant sits in the connector domain of MSH2, a structural region that mediates the critical handoff between mismatch recognition and downstream repair signaling through MLH1.

The Mechanism

Glycine at position 322 is part of a conserved loop in MSH2's connector domain (domain II), which serves as the physical interface with MutL homologs22 MutL homologs
the MLH1-PMS2 complex that executes strand excision after mismatch recognition. Replacing glycine — a structurally flexible amino acid — with aspartate introduces a bulkier, charged side chain that subtly alters connector domain geometry. Functional studies give mixed results: an in vitro MMR assay using human nuclear extracts found statistically significant reduction in repair efficiency (~10% of wild-type33 statistically significant reduction in repair efficiency (~10% of wild-type
Andres et al. 2014, PMC4273566), while an earlier study using purified recombinant protein found no impairment in MSH2-MSH6 complex formation, mismatch binding, or repair activity (Kariola et al. 2008)44 (Kariola et al. 2008). The discrepancy likely reflects assay sensitivity: purification steps may exclude structurally damaged heterodimers, making cell extract assays more representative of in vivo conditions.

The Evidence

The most definitive evidence comes from a genome-scale study in Iceland. Kristmundsdottir et al. (2023, Nature Communications)55 Kristmundsdottir et al. (2023, Nature Communications)
Sequence variants affecting the genome-wide rate of germline microsatellite mutations analyzed whole-genome sequences from 6,084 Icelandic parent-offspring trios and identified rs4987188[A] as a variant that significantly increases transmitted microsatellite de novo mutations: +13.1 mutations in the paternal lineage and +7.8 in the maternal lineage per offspring per generation (P = 3.6×10⁻¹⁰, effect size 0.37 standard deviations). At a baseline of ~64 microsatellite de novo mutations per generation, the A allele represents a ~12–20% increase in germline microsatellite instability, carried symmetrically through both sperm and eggs. Crucially, the similar effect in both sexes indicates that germ cells from both parents are subject to the same MSH2-dependent sequence fidelity process.

ClinVar classification is Benign for Lynch syndrome (expert panel reviewed, InSiGHT September 2013, VCV000001762), based on allele frequency exceeding 1% in the population, lack of disease segregation in Lynch families, and the absence of clear mismatch repair deficiency on standard assays. The germline mutation-rate effect is a distinct phenotype from Lynch syndrome: it does not cause microsatellite instability in tumor DNA, but does modestly increase the per-generation mutation load passed to children.

Smaller case-control studies have explored cancer associations with inconsistent results. A Polish series found MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)66 MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)
Plawski et al. 2017 and a separate Polish cohort reported a protective association with triple-negative breast cancer for the Asp allele, though these studies are small (n ≈ 70–144) and have not been replicated in larger populations.

Practical Actions

For AG heterozygotes, the effect on germline mutation rate is modest — a ~10–15% above-baseline increase in transmitted microsatellite mutations. No specific medical intervention is currently indicated. The finding is most relevant for genetic counseling context in families with unexplained de novo diseases or autism spectrum conditions (where microsatellite instability is one contributor to de novo mutation burden), and for couples undergoing IVF where preimplantation genetic testing for aneuploidy (PGT-A) is already planned.

For AA homozygotes (extremely rare, <0.03% globally), the expected additive effect would be roughly double the heterozygote increase in germline mutation rate. Given how rarely this genotype occurs, robust clinical data specific to AA homozygosity are unavailable; the recommendations remain an extrapolation from the per-allele dosage effect.

Interactions

MSH2 works in obligate heterodimer complexes, so the biological output of Gly322Asp depends on the functional state of its partners — particularly MSH6 (rs2303426 in the MSH2-MSH6 interface region) and MLH1 (rs1799977, already in the GeneOps database). The variant in MLH1 (rs1799977, Ile219Val) sits in the MLH1 ATPase domain that docks with MSH2's connector domain; if a person carries both rs4987188 (MSH2 G322D) and rs1799977 (MLH1 I219V), the connector-domain interface is disrupted from both ends. A compound action covering this combination is worth investigating if familial MMR deficiency studies show additive effects.

EXO1 (rs72755295 and rs1635501 in the GeneOps database) acts downstream of MSH2 in the excision step; MSH2-EXO1 pathway efficiency is relevant to meiotic crossover fidelity. Variants in EXO1 combined with MSH2 G322D could compound the germline mutation-rate phenotype through reduced excision capacity after mismatch recognition.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Repair Fidelity Normal

MSH2 mismatch repair functioning normally

You carry two copies of the common glycine allele at MSH2 position 322. The MSH2 connector domain is structurally intact, supporting normal mismatch recognition and efficient handoff to the MLH1-PMS2 excision complex. Your germline microsatellite mutation rate falls within the typical range of ~64 de novo mutations per generation. About 97% of people globally share this genotype.

AG Reduced Repair Fidelity Reduced

One copy of the MSH2 Gly322Asp variant — modestly elevated germline mutation rate

The Gly322Asp change alters a conserved structural position in MSH2's connector domain — the interface that physically docks with MLH1 after a mismatch is recognized. Functional assays give mixed results: purified-protein studies find no detectable impairment in MSH2-MSH6 complex formation or mismatch binding, while a human cell-extract MMR assay found reduced repair efficiency (~10% of wild-type). The discrepancy likely reflects assay sensitivity: structural perturbations that don't prevent the protein from working entirely can still reduce throughput in conditions that mimic the cellular environment more closely.

The germline consequence measured in Iceland — elevated microsatellite de novo mutations — is consistent with a subtle but real reduction in MMR capacity during gametogenesis. This does not increase cancer risk in the same way as Lynch syndrome mutations, but it does mean that gametes are more likely to carry small insertion/deletion errors at microsatellite loci. Over many generations, such variants can contribute to de novo disease in offspring.

AA Significantly Reduced Repair Fidelity High Risk

Two copies of MSH2 Gly322Asp — substantially elevated germline de novo mutation rate

MSH2 Gly322Asp is codominant — each allele copy contributes independently to reduced MMR throughput in germ cells. For AG heterozygotes, the effect is +13 paternal / +8 maternal extra microsatellite de novo mutations per generation (P = 3.6×10⁻¹⁰). For AA homozygotes, the additive model predicts approximately +26 paternal and +16 maternal extra mutations, representing a ~40% increase above the population baseline of ~64 mutations per generation. No published study has directly measured germline mutation rates in AA homozygotes due to the rarity of this genotype.

The connector domain disruption in AA homozygotes would be more pronounced, with both MSH2 alleles producing the subtly impaired G322D protein. In vitro assays showing ~10% residual MMR activity for G322D would be expected to compound further in the homozygous state.